BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32067844)

  • 1. Do patients who undergo multiparametric MRI for prostate cancer benefit from additional staging imaging? Results from a statewide collaborative.
    Eyrich NW; Tosoian JJ; Drobish J; Montie JE; Qi J; Kim T; Noyes SL; Moriarity AK; Lane BR;
    Urol Oncol; 2020 Jul; 38(7):636.e13-636.e19. PubMed ID: 32067844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of abdominopelvic CT and multiparametric MR imaging for detection of lymph node metastases prior to radical prostatectomy.
    Peabody H; Lane BR; Qi J; Kim T; Montie JE; Moriarity A; Brede CM; Montgomery J;
    World J Urol; 2021 Mar; 39(3):779-785. PubMed ID: 32361876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
    Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
    Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
    Pasoglou V; Larbi A; Collette L; Annet L; Jamar F; Machiels JP; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
    Prostate; 2014 May; 74(5):469-77. PubMed ID: 24375774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and localisation of primary prostate cancer using
    Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
    World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative.
    Chandrasekar T; Denisenko A; Mico V; McPartland C; Shah Y; Mark JR; Lallas CD; Fonshell C; Danella J; Jacobs B; Lanchoney T; Raman JD; Tomaszewski J; Reese A; Singer EA; Ginzburg S; Smaldone M; Uzzo R; Guzzo TJ; Trabulsi EJ
    Urol Oncol; 2023 Aug; 41(8):355.e1-355.e8. PubMed ID: 37357123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.
    Kam J; Yuminaga Y; Krelle M; Gavin D; Koschel S; Aluwihare K; Sutherland T; Skinner S; Brennan J; Wong LM; Louie-Johnsun M
    BJU Int; 2019 Aug; 124(2):297-301. PubMed ID: 30714285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bone scintigraphy and
    Pyka T; Okamoto S; Dahlbender M; Tauber R; Retz M; Heck M; Tamaki N; Schwaiger M; Maurer T; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric MRI - local staging of prostate cancer and beyond.
    Caglic I; Kovac V; Barrett T
    Radiol Oncol; 2019 May; 53(2):159-170. PubMed ID: 31103999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice.
    Zawaideh JP; Sala E; Shaida N; Koo B; Warren AY; Carmisciano L; Saeb-Parsy K; Gnanapragasam VJ; Kastner C; Barrett T
    Eur Radiol; 2020 Jul; 30(7):4039-4049. PubMed ID: 32166495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
    Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
    Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
    Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.